FDA approves Sanofi-Regeneron’s Dupixent for treatment of 'smoker's lung'

The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDA:SNY) and Regeneron (NASDAQ:REGN) for the expanded use of their blockbuster drug, Dupixent, in treating chronic lung disease, commonly known as "smoker's lung" or chronic obstructive pulmonary disease (COPD).

This approval is expected to significantly boost sales for the drug, which is already a top revenue generator for both companies.

In 2023, Sanofi recorded €10.72 billion ($11.94 billion) in sales for Dupixent, including Regeneron’s share.

Industry analysts estimate that by 2030, Dupixent could generate over €21 billion in annual sales, according to data from LSEG.

COPD is a progressive lung disease that leads to restricted airflow, predominantly affecting cigarette smokers.

However, the condition can also result from air pollution and occupational hazards.

With this new FDA approval, Dupixent is positioned to make a major impact in the treatment of this chronic condition, offering hope to millions of patients suffering from COPD while potentially reshaping the market for respiratory disease treatments.